8318 RESULTS
COMMENT The authors have developed a microfluidics-based, solid-state impedance measure (interdigitated microelectrode [IME] sensor system) of monoclonal antibody 6E10-Aβ interactions which they claim can measure plasma Aβ levels on a scale of 0.1 pg/ml. The ...
COMMENT While this study demonstrated the lack of benefit of a nonselective NSAID for chronic use, targeting inflammation as a contributor to cognitive loss in the context of accumulation of amyloid remains a viable goal. The ability to slow cognitive decline ...
COMMENT We share the view of Drs. Tapias and Beal that misfolded proteins such as Aβ and tau impair all aspects of mitochondrial functions. In fact, we have a long-standing interest in how Aβ and tau impair neuronal functions, dating back to 2005 when we combined ...
COMMENT It is exciting to see continued interest surrounding cellular senescence in neurodegenerative diseases. Prior studies have reported senescent cells in postmortem human brains from patients with Alzheimer’s disease (Bhat et al., 2012; Musi et al., 2018), ...
COMMENT We understand Dr. Rebeck’s comment and his (and editorialists Drs. Hershey’s and Lipton’s) evident desire to consider all possibilities before abandoning NSAIDs altogether for prevention of AD. We offer two caveats, however: 1) We question whether it’s ...
COMMENT This is clearly an important study. However, prevention in an epidemiology study is likely delay of initial pathology, whereas prevention in this type of study would likely be delay of symptoms arising from existing pathology. Thus, this negative NSAID ...
COMMENT One weakness of epidemiological evidence is the association does not permit cause-effect relationships to be determined. There are physiological reasons some individuals elect to take NSAIDs and others do not. Instead of the NSAIDs themselves providing ...
COMMENT The observation that NSAIDs do not significantly slow disease progression when administered to asymptomatic people in their 60s at high risk of Alzheimer’s disease does not debunk any of the potential benefits mediated by reducing neuroinflammation over ...
COMMENT I side with the closing comments of David Knopman: "To be blunt, Aβ lowering seems to be an ineffective approach, and it is time to focus on other targets to move therapeutics for Alzheimer’s disease forward." We do need a fresh start and also ...
COMMENT Aging, the most important risk factor for AD, is linked to reductions in mitophagy. This is a remarkable and outstanding paper since it ties tau phosphorylation and amyloid pathology to mitochondrial dysfunction and defective mitophagy. These findings ...
COMMENT There really is no way to spin this that avoids the conclusion that these findings weaken, if not falsify, the hypothesis that Aβ production produces Alzheimer’s disease. If there were no effect, there might be some wiggle room left. The fact is that, ...
COMMENT This is a very interesting and important study. For the first time, it is convincingly shown (at the group level) that former National Fotboll League players, with cognitive and behavioral symptoms, have increased tau PET ligand retention in several ...
COMMENT This is a welcome and carefully written paper. It is the first good evidence that tau imaging can detect a signal in chronic traumatic encephalopathy, but the authors make very clear that this is a long way off from being a useful diagnostic test for ...
COMMENT Developing in vivo biomarkers of CTE is absolutely critical for efforts to understand basic questions about disease prevalence, mechanisms, susceptibility and resilience factors, and ultimately for drug development. This paper by Stern and colleagues ...
COMMENT The INTREPAD trial is notable as a follow-up to questions raised by the ADAPT naproxen trial, e.g., if starting patients earlier, prior to any decline, and treating for a full two years with 400 mg naproxen daily can impact rates of decline and/or tau ...
